[IOVA]

Iovance Therapeutics shares hit their highest level since 2024 as analysts raised their guidance. If the price breaks above the resistance level at 11.17, take profit at $11.17; if the price falls below the support level at 7.66, cut losses at $7.66. The current stock price of $14.91 significantly exceeds the 20-day resistance level of $11.17, indicating strong upward momentum. Based on the overbought signal with an RSI of 75.7, the bullish alignment of moving averages, and a recent 7-day volatility of +9.7%, a purchase was considered. RSI (14) at 75.7 (overbought), moving averages in a bullish alignment (uptrend), trading volume at 0.89x the 20-day average (volume decreasing), and a +9.7% change over the past 7 days (rising trend). The forecast predicted the stock price would continue its upward trend and yield a 4.5% return, but it actually resulted in a -13.1% loss, failing to reach the stop-loss level. The erroneous decision to buy—despite the RSI already being in the overbought zone at 75.7 and trading volume being below average—was caused by overconfidence that the current price, which significantly exceeded the resistance level, was sustainable. On the other hand, the recent 7-day volatility of +9.7% and the bullish alignment of moving averages suggested upside potential, but this was insufficiently verified. For the next trades, entry should be withheld when the RSI is 70 or above, and a cautious approach should be taken even when trading volume is below average. In addition, take profits when the price rises by a certain percentage (e.g., 5%) after breaking through a resistance line, and limit risk by setting a more conservative stop-loss level. General disclosures such as SEC Form 8-K should be viewed neutrally, and the increasing trend in thematic news should be continuously monitored. The historical records of a +28.8% surge on 2026-08-14 and a +12.4% increase on 2026-08-06 showed a pattern of rapid rallies following positive news, raising expectations for a similar upward move upon this guidance hike, but the outcome was different.

Iovance Biotherapeutics' stock price reached a 52-week high of 6.94 USD. The current price of $6.98 is above the resistance level of $6.92, so if it fails to establish a breakthrough and pulls back, we will allow for a decline down to the support level of $3.96 and respond with a stop-loss. Conversely, if the upward trend continues, we will set a profit-taking target around the resistance level of $6.92. The current price of $6.98 slightly exceeds the 20-day high resistance level of $6.92, while the support level is positioned at $3.96. I will monitor whether it successfully breaks through the all-time high and consider entering. The technical indicators at the entry point show an RSI(14) of 68.6, a positive alignment of moving averages, a trading volume at 0.83 times the 20-day average, and a recent 7-day volatility of +49.5%. At the time of entry, the current price of $6.98 was slightly above the resistance level of $6.92, which was the 20-day high, while the support level was at $3.96. A predicted return of 3.5% was set, monitoring whether the stock would successfully break through to a new high. However, the actual result significantly exceeded the prediction, recording a return of 18.8%, resulting in an OVERHIT designation. At that time, the RSI was 68.6, with a positive alignment of moving averages and a strong volatility of +49.5% over the past 7 days. Despite this, trading volume was somewhat limited at 0.83 times the 20-day average, leading to a conservative view on the potential for such strong upward momentum, which contributed to the difference between the prediction and the actual result. In the upcoming trades, if there is an attempt to reach a new high accompanied by strong volatility while the moving averages are in a positive alignment, I will reflect strategic flexibility in the next trades by keeping the profit-taking target open, even if the trading volume is somewhat lower than the 20-day average, without underestimating the momentum of the trend. There is a historical precedent showing a price reaction of +12.4% on August 6, 2026.

Iovance's stock price surged due to the strong performance related to Amtagvi announced by the company. Based on the current price, consider taking profits with a target at the 20-day resistance level ($5.64), but respond with a stop-loss if it falls below and threatens the support level ($3.76). The current price is above the previous 20-day resistance level ($5.64) and is positioned near a new high, which supports the consideration for entry based on a trend of strength. RSI(14) is 44.3, moving averages are in a positive alignment, trading volume is 0.97 times the 20-day average, and the recent 7-day volatility is recorded at -11.4%. At the time of the forecast, it was noted that the stock was trading above the 20-day resistance level ($5.64) and was near its all-time high, leading to an expected return of 3.2%. However, the actual result recorded a 14.7% increase, resulting in an OVERHIT designation. Thanks to positive news regarding Amtagvi's strong performance, it was confirmed that the upward trend in the moving averages was much stronger than anticipated. Although the trading volume was 0.97 times the 20-day average, the strong momentum observed indicates that the impact of the positive news generated a strong buying interest that surpassed the simple numerical values of technical indicators (such as RSI 44.3). Through this trading, it has been confirmed that stocks accompanied by positive news near their all-time highs can exhibit greater upward momentum than expected. In future trading, if positive news coincides with the initial stage of a bullish alignment or a breakout above all-time highs, we will adopt a strategy that remains flexible, allowing for the possibility of trend sustainability in addition to mechanical target prices.